IGC Pharma, Inc. IGC
$0.27
+1.95%
at last close
Market Cap$27.54 million
P/E Ratio—
Div Yield—
Volume280.6K
52-Week Range
$0.23$0.50
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $6.00 (+2109.1% upside)
Key Stats
- Today's Range
- $0.27 – $0.28
- 50-Day Range
- $0.23 – $0.34
- 52-Week Range
- $0.23 – $0.50
- Volume
- 281K shs
- Average Volume
- 931K shs
- Market Cap
- $27.54 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.49
- Price / Sales
- —
Short Interest
- Short Interest
- 0.59%
- Days to Cover
- 1.00
About IGC Pharma, Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Related Stocks
Compare head-to-head: IGC vs LLY·IGC vs JNJ·IGC vs ABBV·IGC vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.